Tazeen Ahmad
BofA Securities, Research Division

Biotech Analyst at the bank. It's my pleasure to have with me our next presenting company, Neurocrine. Sitting up here on stage, there are a couple of familiar faces, Matt Abernethy, who is, of course, Chief Financial Officer; as well as Todd Tushla. Your job again, sir?

Todd Tushla

I'm the current Vice President of Investor Relations.

Tazeen Ahmad
BofA Securities, Research Division

Okay. Just wanted to clarify.

Matthew Abernethy
Chief Financial Officer

He did tell me this is his new title from you this morning, your favorite person. Can you confirm that?

Tazeen Ahmad
BofA Securities, Research Division

Yes. I did say that. I did in fact say that. We'll put that on your card.

Todd Tushla

Thank you.

Tazeen Ahmad
BofA Securities, Research Division

So maybe, Matt, for the few people who aren't as familiar with the company, can you just give us a quick overview of Neurocrine and then we can go into some of the more recent updates that have been happening?

Matthew Abernethy
Chief Financial Officer

Sure. We are going to be making forward-looking statements, as you can imagine. So check out the latest SEC filings. I'm sure you're excited about that update. But I was reflecting coming out here, Tazeen 8.5 years ago, I joined Neurocrine. In our first conversation, I remember it because you've got a good perspective on things. And if I recall, the conversation was all around elagolix and a little bit around INGREZZA.

And so when you fast forward over the last 8.5 years now, we sit here